Will the results be positive?
Market price is close to the intrinsic forecast probability, but slightly under. Buying yes shares seems attractive given the forecast of 60% probability of a positive outcome and available budget.
The market price of ~0.50 significantly undervalues the stock. The intrinsic probability of success is higher than 50% given the strong rationale and data readouts. Buying YES shares at this level offers a positive...
Intrinsic estimate (~55%) is only marginally above market price (~50%). The edge is too small given the high trial uncertainty, Phase 2 status, and recent primary completion. No compelling mispricing to act on.
With an intrinsic probability of 55% and a market price of 50%, the pricing gap is too narrow to justify tying up capital, especially considering the high failure rate in LN trials and likely timeline delays.
Intrinsic 58% > market 50% (8% edge). YES undervalued. Max buy $611 feasible within cash/cap, positive EV trade.
